title: [Comparison of management of advanced cancer in various organs].
abstract: The management of advanced cancer presents the greatest challenge to physicians involved in oncology. There will usually be a large burden of disease; cure is unlikely; and the needs of the patient in terms of pain control and palliation will also be important over and above the direct treatment of the disease. Different issues will arise depending on the site and pathological type of the cancer. Increasingly over the past few years, treatment protocols and guidelines have been developed for different cancers, but these can only be rough guides rather than definite treatment recommendations. Additionally in most cancers advanced disease offers the opportunity for evaluation of new treatments in Phase II studies and other trials. With the new generation of molecular targeted therapies, such as EGFR inhibitors, striking results are being seen in advanced disease that compare favourably with what has been seen previously. Other agents such as those which attack the tumour vasculature may also have promise in this setting. Palliation is also an important aspect of the management of advanced disease, and pain control in particular is an important component of patient management. In summary, the treatment of advanced disease provides a test bed for new agents, but this need to develop better cancer therapies must be balanced against patient needs for a pain-free and comfortable end to life.
authors.affiliation: Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba.
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: T
authors.initials: T
authors.lastname: Saeki
authors.forename: K
authors.initials: K
authors.lastname: Kawai
authors.forename: K
authors.initials: K
authors.lastname: Aiba
authors.forename: S
authors.initials: S
authors.lastname: Isonishi
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: S
authors.initials: S
authors.lastname: Sone
authors.forename: T
authors.initials: T
authors.lastname: Tamura
authors.forename: S
authors.initials: S
authors.lastname: Tsukagoshi
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Miki
authors.forename: M
authors.initials: M
authors.lastname: Kato
authors.forename: O
authors.initials: O
authors.lastname: Mikami
authors.forename: A
authors.initials: A
authors.lastname: Barge
authors.forename: G
authors.initials: G
authors.lastname: Blackledge
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D059408:Pain Management; D010166:Palliative Care; D011788:Quality of Life